Updates are available Correction dated 2022-01-01

Article History

Received: 14 February 2022

Accepted: 12 May 2022

First Online: 13 June 2022

Change Date: 28 July 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s40463-022-00589-3

Declarations

:

: Institutional ethics review necessity was inquired from McMaster University’s institutional Hamilton Integrated Research Ethics Board (HiREB), and determined to not be required for this study.

: Not applicable.

: No conflicts of interest related to this study.

: DD Sommer: GlaxoSmithKline, Sanofi: principal investigator, advisory board; Medtronic: speaker. KA Smith: advisory board fees from Sanofi, speaker fees from Mylan. MA Tewfik: Sanofi: principal investigator and consultant; AstraZeneca: principal investigator and consultant; Stryker: consultant and speaker; Novartis: consultant and speaker; Pentax: consultant; GSK: consultant; Mylan: speaker; Thieme: royalties. A Thamboo: Storz consultant; Medtronic speaker honorarium; Stryker consultant; Sanofi advisory board; GSK speaker honorarium.